Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Odense University Hospital Aarhus University Hospital H. Lundbeck A/S |
---|---|
Information provided by: | Odense University Hospital |
ClinicalTrials.gov Identifier: | NCT00162968 |
Many people with polyneuropathy suffer from pain which is difficult to treat. Escitalopram is a relatively new drug used in the treatment of depression. Escitalopram’s action mechanism on the brain suggests that escitalopram also may have an effect on neuropathic pain. This study will test the efficacy of escitalopram in patients with painful polyneuropathy.
Condition | Intervention | Phase |
---|---|---|
Pain Polyneuropathies |
Drug: escitalopram |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | Escitalopram as a Treatment for Pain in Polyneuropathy. A Double-Blind, Randomized, Placebo Controlled Trial. |
Estimated Enrollment: | 50 |
Study Start Date: | December 2004 |
Study Completion Date: | April 2007 |
Tricyclic antidepressants appear to be the most efficacious treatment of painful polyneuropathy. However, these drugs are contraindicated in some patients and a substantial number of patients decline treatment due to side-effects. Therefore, effective drugs that are better tolerated are needed. Clinical and basic research has demonstrated that drugs with serotonergic action can alleviate neuropathic pain. Escitalopram increases serotonin concentration in the central nervous system, suggesting that it might be a potential alternative to current treatments of neuropathic pain. The aim of this study is to test if escitalopram would relieve painful polyneuropathy.
Comparisons: Treatment with 20 mg escitalopram daily will be compared in a cross-over design with placebo. Each treatment period will last 6 weeks. During the last week of each treatment period, the dose will be tapered.
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Denmark | |
Dept. of Neurology, Odense University Hospital, Sdr. Boulevard 29 | |
Odense, Denmark, 5000 | |
Danish Pain Research Center, Aarhus University Hospital, Noerrebrogade 44 | |
Aarhus, Denmark, 8000 |
Principal Investigator: | Soeren H Sindrup, MD, PhD | Odense University Hospital, Dept. of neurology |
Study ID Numbers: | escit01 |
Study First Received: | September 9, 2005 |
Last Updated: | April 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00162968 |
Health Authority: | Denmark: Danish Medicines Agency |
polyneuropathies pain drug effects escitalopram serotonin uptake inhibitors |
Neuromuscular Diseases Peripheral Nervous System Diseases Polyneuropathies Pain |
Dexetimide Citalopram Serotonin |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents |
Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Serotonin Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |